Thermo Fisher Forecasts Revenue Growth in 2025 Amid Easing Market Challenges

Revenue Forecast:
Thermo Fisher Scientific predicts a revenue uptick in 2025, expecting headwinds such as reduced COVID-19 testing revenue to ease.

Earnings Guidance:
The company raised its full-year adjusted EPS guidance to $21.35 to $22.07, maintaining its revenue forecast within the range of $42.4 billion to $43.3 billion.

Segment Performance:
The Analytical Instruments segment saw a 3% organic growth, while Specialty Diagnostics experienced a 4% increase. Life Sciences Solutions reported a 2% decline.

Market Recovery:
CEO Marc Casper noted modest improvements in market conditions, expecting a return to organic growth in the fourth quarter of 2024.

Biotech Funding:
Thermo Fisher anticipates improved biotech funding, which could boost spending on its tools and services, particularly in drug development.

Strategic Growth:
The company has made strategic acquisitions, such as Olink, and launched new products like the Thermo Ili scanning transmission electron microscope and the Biosystems sequential DNA kit.